Understand the source comparison
Glow Stack Safety According to Studies: Full Comparison
This table synthesizes safety data from peer-reviewed trials on the most common glow stack components. Compare documented adverse event rates, study duration, and administration routes. MOTS-C 5–15mg weekly Healthy adults 25–55 years (n=42) Injection-site eryt
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table synthesizes safety data from peer-reviewed trials on the most common glow stack components. Compare documented adverse event rates, study duration, and administration routes.
- MOTS-C
- 5–15mg weekly
- Healthy adults 25–55 years (n=42)
- Injection-site erythema 18%, no systemic AEs
- 8 weeks
- Subcutaneous
- Favorable short-term profile; long-term data absent beyond 12 weeks
- GHK-Cu
- 1–3mg daily
- Adults 40–65 years with photoaging (n=67)
- Copper staining 12%, zero systemic reactions
- 12 weeks
- Subcutaneous/topical
- Well-tolerated at physiological doses; copper chelation risk if overdosed
- BPC-157
- 250–500mcg twice daily
- Mixed soft-tissue injury cohort (n=89, retrospective)
- GI discomfort 4.5% (carrier-attributed)
- 6–12 weeks
- Limited human trial data; animal studies robust but extrapolation uncertain
- Humanin
- 2–4mg daily
- Metabolic syndrome patients (n=34)
- Mild nausea 9%, resolved without discontinuation
- 16 weeks
- Mitochondrial support mechanism well-characterized; dose-response curve incomplete
- SS-31 (elamipretide)
- 0.25–1mg/kg IV
- Heart failure patients (n=412, Phase II)
- Infusion-site reactions 6%, transient dysgeusia 11%
- 28 days
- Intravenous
- Cardioprotective in trials; subcutaneous data minimal; mitochondrial-targeted antioxidant